The new ACC/AHA guidelines on treatment of blood cholesterol focus on intensity of statin therapy rather than target levels of lipids. Early studies show substantial reductions in LDL-cholesterol level with antibodies against PCSK9. MicroRNA silencing and gene-repair techniques to treat dyslipidaemia are promising strategies under development.
Subscribe to Journal
Get full journal access for 1 year
only $17.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Stone, N. J. et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation http://dx.doi.org/10.1161/01.cir.0000437738.63853.7a.
Desai, N. R. et al. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of NCEP-ATP III LDL-C goals among high risk patients: an analysis from the LAPLACE-TIMI 57 trial. J. Am. Coll. Cardiol. http://dx.doi.org/10.1016/j.jacc.2013.09.048.
Cohen, J. C., Boerwinkle, E., Mosley, T. H. Jr & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264–1272 (2006).
Desai, N. R. et al. AMG 145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy. Circulation 128, 962–969 (2013).
Stein, E. A. et al. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 128, 2113–2120 (2013).
Koren, M. J. et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia. Circulation http://dx.doi.org/10.1161/CIRCULATIONAHA.113.007012.
McKenney, J. M. et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J. Am. Coll. Cardiol. 59, 2344–2353 (2012).
Rotllan, N., Ramírez, C. M., Aryal, B., Esau, C. C. & Fernández-Hernando, C. Therapeutic silencing of microRNA-33 inhibits the progression of atherosclerosis in Ldlr−/− mice—brief report. Arterioscler. Thromb. Vasc. Biol. 33, 1973–1977 (2013).
Eberlé, D. et al. Inducible Apoe gene repair in hypomorphic ApoE mice deficient in the low-density lipoprotein receptor promotes atheroma stabilization with a human-like lipoprotein profile. Arterioscler. Thromb. Vasc. Biol. 33, 1759–1767 (2013).
D. P. Mikhailidis declares that he has given talks, attended conferences, and participated in trials and advisory boards sponsored by Genzyme and MSD. V. G. Athyros declares no competing interests.
About this article
Cite this article
Mikhailidis, D., Athyros, V. New statin guidelines and promising novel therapeutics. Nat Rev Cardiol 11, 72–74 (2014). https://doi.org/10.1038/nrcardio.2013.209
Current Medical Research and Opinion (2019)
Drug Metabolism and Personalized Therapy (2018)
The DrugPattern tool for drug set enrichment analysis and its prediction for beneficial effects of oxLDL on type 2 diabetes
Journal of Genetics and Genomics (2018)